Approval · Notice of Compliance 29267 · 2022
JAMP RIZATRIPTAN: Notice of Compliance 29267
Issued October 20, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29267
- Date
- October 20, 2022
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Administrative: Labelling Update (to Match Licensor)
- Canadian reference product
- MAXALT
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JAMP RIZATRIPTAN | Not yet assigned | — |
Medicinal ingredients
- RIZATRIPTAN 5 MG per TAB
- RIZATRIPTAN 10 MG per TAB